TSMHT
TCRT icon

Thurston Springer Miller Herd & Titak’s Alaunos Therapeutics TCRT Stock Holding History

Thurston Springer Miller Herd & Titak’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-21
Closed -$101 – 1269
2025
Q2 		$101 Hold
21
– – ﹤0.01% 1621
2025
Q1 		$30 Hold
21
– – ﹤0.01% 1678
2024
Q4 		$40 Buy
+21
New +$47 ﹤0.01% 1323

Other funds holding TCRT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Thurston Springer Miller Herd & Titak's TCRT Position: Q3 2025 in Review

Thurston Springer Miller Herd & Titak sold out of Alaunos Therapeutics (TCRT) in Q3 2025, closing a stake of 21 shares — an estimated $101 sold.

Thurston Springer Miller Herd & Titak first reported a position in TCRT in Q4 2024 and held it in 3 quarters. The position peaked at $101 in Q2 2025. 26 funds tracked by Wall St. Rank hold TCRT as of Q3 2025.

  • Thurston Springer Miller Herd & Titak reported no remaining Alaunos Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Thurston Springer Miller Herd & Titak sold 21 Alaunos Therapeutics shares in Q3 2025, an estimated $101.
  • Thurston Springer Miller Herd & Titak first reported a position in Alaunos Therapeutics in Q4 2024 and held it in 3 quarters.
  • Thurston Springer Miller Herd & Titak's Alaunos Therapeutics position peaked at $101 in Q2 2025.
  • 26 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2025.

Based on Thurston Springer Miller Herd & Titak's 13F filing for Q3 2025, filed 7 Oct 2025.